Changes in Beneficial Ownership · 4
Arbutus Biopharma Corporation
ABUSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- Arbutus Biopharma Corp
- Issuer CIK
- 0001447028
- Trading symbol
- [ABUS]
Reporting owner 1
- Name
- Roivant Sciences Ltd.
- Reporting owner CIK
- 0001635088
- Relationship
- Director · 10% owner
- Address
- C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM, X0, X0, SW1H0DB
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Shares | 2026-10-01 | D · Form 4 | 8,967,383 | D | 5.00 | 29,880,079 | D |
Table key
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- D
- Direct
Remarks
The Reporting Person may be deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Matthew Gline (a director of the Issuer who serves as Chief Executive Officer of the Reporting Person and is an employee of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person) and Joseph Bishop (who is an employee of RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person. Lindsay Androski, who also serves on the board of directors of the Issuer, is an employee of RSI and separately serves as President and Chief Executive Officer of the Issuer.
Signature 1
- Signed
- By: /s/ Keyur Parekh, as Authorized Signatory
- Date
- 2026-10-05